Base title: prevent preclinical drug development program: preclinical efficacy and intermediate endpoint biomakers task order title: vaccines against fusobacterium for FAP-and lynch…
Ended Awarded Last action
- Contract number
- 75N91022F00001
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Temple University-Of The Commonwealth System Of Higher Education
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,051,148
Award facts
- Contract value 100% obligated
- $2,051,148.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19111, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $515,612 | |
| Exercise an Option | $921,373 | |
| Original award | $614,163 |
About this award
The National Cancer Institute (NCI) awarded a firm fixed-price delivery order valued at $2.05M to The Institute for Cancer Research (ICR), a non-profit subsidiary of Temple University, on June 15, 2022. This task order, which extends through May 14, 2026, supports the development of vaccines against Fusobacterium for colorectal cancer immunoprevention in patients with familial adenomatous polyposis (FAP) and Lynch syndrome. The work will be performed at ICR's facility in Philadelphia, Pennsylvania. This award is issued without a set-aside designation and represents a competitive delivery order under the PREVENT Preclinical Drug Development Program, a $150M indefinite delivery contract vehicle managed by the NCI that structures drug and vaccine development from discovery through clinical evaluation stages.
The delivery order falls within the Preclinical Efficacy and Intermediate Endpoint Biomarkers pool of the PREVENT program, which focuses on evaluating candidate chemopreventive and immunopreventive regimens and identifying relevant pharmacodynamic and efficacy biomarkers. ICR brings substantial expertise in preclinical cancer research and drug development, having received multiple prior awards under the PREVENT vehicle for investigations into various cancer types and prevention strategies. The institute's work under this task order will contribute to NCI's broader cancer prevention mission by advancing preclinical evidence supporting vaccine-based approaches to reducing colorectal cancer risk in genetically predisposed populations.
Description
Base title: prevent preclinical drug development program: preclinical efficacy and intermediate endpoint biomakers task order title: vaccines against fusobacterium for FAP-and lynch syndrome-associated colorectal cancer immunoprevention
Quick answers
Who was awarded contract 75N91022F00001?
75N91022F00001 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on June 15, 2022.
How much is contract 75N91022F00001 worth?
The government has obligated $2,051,148 on 75N91022F00001.
Is contract 75N91022F00001 an order under another contract?
Yes. 75N91022F00001 is a delivery order under 75N91019D00022, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91022F00001 competed?
The extent of competition for 75N91022F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award